Health Sciences Authority (HSA) is Singapore’s national authority regulating health products, including medications. Every month, HSA publishes a list of medications that are newly approved or medications with newly approved indication(s). This list can be found on HSA’s website.
January 2022
- New drugs approved: 4
- New drug indications approved: 4
New drugs approved
| Product name | Active ingredient(s) | Dosage Form | Strength of dosage form | Route of Administration | Indication(s) | Pharmaceutical company | Approval Date |
| Cibinqo | Abrocitinib | Tablet | 50mg, 100mg, 200mg | Oral | Moderate-to-severe atopic dermatitis in adults (age 18 years and above) | Pfizer | 05 Jan 2022 |
| Salonpas | Diclofenac | Gel | 1% | Topical | Relief of aches, pains and inflammation | Hisamitsi Pharmaceutical | 17 Jan 2022 |
| Contrave | Naltrexone / Bupropion | Tablet (Sustained Release) | 8mg / 90mg | Oral | Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults | Inova Pharmaceuticals | 03 Jan 2022 |
| Trodelvy | Sacituzumab govitecan | Vial | 180mg | Injection | Treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) | Everest Medicines | 31 Jan 2022 |
New drug indications approved
| Product name | Active ingredient(s) | Dosage Form | Strength of dosage form | Route of Administration | Indication(s) | Pharmaceutical company | Approval Date |
| Symvenu | Cariprazine | Capsule | 1.5mg, 3mg, 4.5mg, 6mg | Oral | (i) Manic or mixed episodes associated with bipolar I disorder in adult patients (ii) Depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients. |
Mitsubishi Tanabe Pharma | 25 Jan 2022 |
| Zavicefta | Ceftazidime / Avibactam | Vial | 2g / 0.5g | Injection | (i) Complicated Intra-Abdominal Infection (cIAI) (ii) Complicated Urinary Tract Infection (cUTI), including Pyelonephritis (iii) Hospital-acquired Pneumonia (HAP), including ventilator associated pneumonia (VAP) (iv) Bacteremia in association with (i) to (iii) |
Pfizer | 26 Jan 2022 |
| Xyntha | Moroctocog Alfa (AF-CC) | Vial | 250IU, 500IU, 1000IU, 2000IU | Injection | Routine and surgical prophylaxis in patients with hemophilia A | Pfizer | 28 Jan 2022 |
| Keytruda | Pembrolizumab | Vial | 25mg | Injection | (i) Metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) (ii) Relapsed or refractory classical Hodgkin lymphoma (cHL) (iii) Locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) |
MSD Pharma | 04 Jan 2022 |
